Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

1. Grávalos, C.
2. Gómez-Martín, C.
3. Rivera, F.
4. Alés, I.
5. Queralt, B.
6. Márquez, A.
7. Jiménez, U.
8. Alonso, V.
9. García-Carbonero, R.
10. Sastre, J.
11. Colomer, R.
12. Cortés-Funes, H.
13. Jimeno, A.